| Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. | |
| | |
MedLine Citation:
|
PMID: 20185013 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Chinese red yeast rice is a dietary supplement containing monacolins, unsaturated fatty acids, and phytosterols capable of lowering low-density lipoprotein (LDL) cholesterol. Few studies have reported on its use in clinical practice or in statin-intolerant patients. We reviewed approximately 1,400 clinical charts and identified 25 patients treated with red yeast rice for > or =4 weeks. The patients were included if they had pre- and post-treatment lipid levels without simultaneous changes in other lipid-lowering medications. These patients had experienced myalgias (68%), gastrointestinal intolerance (16%), and/or elevated alanine aminotransferase levels (8%) with previous use of other lipid-lowering agents. The total cholesterol decreased 15% (-37 +/- 26 mg/dl, p <0.001) and LDL cholesterol decreased 21% (-35 +/- 25 mg/dl, p <0.001) during 74 +/- 39 days of treatment. Most (92%) patients tolerated the treatment, and many (56%) achieved their LDL cholesterol goal. In patients unable to tolerate daily statin use, the total cholesterol level decreased 13% (-33 +/- 10 mg/dl, p <0.001) and LDL cholesterol decreased 19% (-31 +/- 4 mg/dl, p <0.001). In conclusion, red yeast rice modestly decreased total and LDL cholesterol, was well-tolerated, and was an acceptable alternative in patients intolerant of other lipid-lowering medications. |
| | |
Authors:
|
Carmelo V Venero; Jose V Venero; Dale C Wortham; Paul D Thompson |
Related Documents
:
|
20400493 - Lipid lowering goals: back to nature? 11375333 - Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia ... 10917903 - Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents s... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The American journal of cardiology Volume: 105 ISSN: 1879-1913 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-26 Completed Date: 2010-04-06 Revised Date: 2010-07-23 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 664-6 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
University of Tennessee Medical Center, Knoxville, Tennessee, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Biological Products / therapeutic use* Cholesterol / blood Cohort Studies Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects, therapeutic use* Hyperlipidemias / drug therapy* Male Middle Aged Muscular Diseases / chemically induced Retrospective Studies Risk Factors Treatment Outcome Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Biological Products; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Triglycerides; 0/red yeast rice; 57-88-5/Cholesterol |
| Comments/Corrections | |
Comment In:
|
Am J Cardiol. 2010 Aug 1;106(3):448
[PMID:
20643262
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Safety and Efficacy of Ezetimibe Added to Atorvastatin Versus Up Titration of Atorvastatin to 40 mg ...
Next Document: Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Athe...